Hanna Ludwisiak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hanna Ludwisiak has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Julia Owsik
Wroclaw Medical University
8 shared publications - Małgorzata Dorożalska
Wroclaw Medical University
8 shared publications - Weronika Wrona
Wroclaw Medical University
8 shared publications - Wiktoria Wdowiak
Wroclaw Medical University
8 shared publications - Aleksandra Glapa
Wroclaw Medical University
4 shared publications - Anna Wojdas
Wroclaw Medical University
4 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 79, 76662
Exercise Therapy in the Management of Chronic Low Back Pain: Current Evidence and Practical Implications – A Narrative Review
Background: Chronic low back pain (CLBP) is a multifactorial condition influenced by physical, psychological, and social factors. Exercise therapy is a core element of conservative management, yet it encompasses highly heterogeneous interventions. Aim: This narrative review summarizes current evidence on the effectiveness and safety of exercise therapy for CLBP, focusing on exercise modalities, optimal doses, individualization, special populations, delivery methods, and practical implications. Material and Methods: A narrative literature review was conducted primarily through PubMed and completed in August 2026. The search was limited to studies published in the preceding five years involving adult participants with CLBP, including systematic reviews, meta-analyses, and randomized controlled trials. Results: Exercise therapy produces a clinically important reduction in pain intensity (approx. 15 points on a 0–100 scale) and a smaller improvement in functional disability compared to no treatment or placebo. No single exercise modality has demonstrated consistent superiority. Regular participation (15–30 minutes per session, three times per week, programs lasting at least 16 weeks) is favorable. Benefits are most evident versus inactive controls and diminish when compared with other active treatments. Adherence, individualization, and continued physical activity are key determinants of success. Exercise is generally safe, with mild, transient musculoskeletal symptoms being the most common adverse effects. Conclusions: Exercise therapy is an effective, adaptable, and safe non-pharmacological intervention for CLBP. Outcomes depend less on the specific modality than on adequate dosage, sustained adherence, and a patient-centred approach integrating individual preferences, functional goals, and psychological strategies.
- 11 November 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 79, 76662
Open AccessExercise Therapy in the Management of Chronic Low Back Pain: Current Evidence and Practical Implications – A Narrative Review
Background: Chronic low back pain (CLBP) is a multifactorial condition influenced by physical, psychological, and social factors. Exercise therapy is a core element of conservative management, yet it encompasses highly heterogeneous interventions. Aim: This narrative review summarizes current evidence on the effectiveness and safety of exercise therapy for CLBP, focusing on exercise modalities, optimal doses, individualization, special populations, delivery methods, and practical implications. Material and Methods: A narrative literature review was conducted primarily through PubMed and completed in August 2026. The search was limited to studies published in the preceding five years involving adult participants with CLBP, including systematic reviews, meta-analyses, and randomized controlled trials. Results: Exercise therapy produces a clinically important reduction in pain intensity (approx. 15 points on a 0–100 scale) and a smaller improvement in functional disability compared to no treatment or placebo. No single exercise modality has demonstrated consistent superiority. Regular participation (15–30 minutes per session, three times per week, programs lasting at least 16 weeks) is favorable. Benefits are most evident versus inactive controls and diminish when compared with other active treatments. Adherence, individualization, and continued physical activity are key determinants of success. Exercise is generally safe, with mild, transient musculoskeletal symptoms being the most common adverse effects. Conclusions: Exercise therapy is an effective, adaptable, and safe non-pharmacological intervention for CLBP. Outcomes depend less on the specific modality than on adequate dosage, sustained adherence, and a patient-centred approach integrating individual preferences, functional goals, and psychological strategies.
- Open Access
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76161
The effects of high intensity interval training (HIIT) on insulin sensitivity and metabolic health in adults with prediabetes
Background. Prediabetes elevates lifetime risk of type 2 diabetes and cardiovascular disease. Moderate-intensity continuous training (MICT) improves metabolic health but is limited by time demands. High-intensity interval training (HIIT) is a time-efficient alternative that can match or exceed MICT benefits for insulin sensitivity and glycemic control, yet optimal protocols remain unclear. Aim. To evaluate the effects of HIIT on insulin sensitivity and metabolic health in adults with prediabetes. Material and methods. PubMed, Scopus and Google Scholar were searched for English-language peer-reviewed studies (2015–2026) on HIIT and insulin sensitivity or metabolic outcomes in adults with prediabetes. Eligible randomised controlled trials, controlled trials, observational studies and reviews were screened by title/abstract and full text after duplicate removal; reference lists were also hand-searched. Results. HIIT improved muscle and whole-body insulin sensitivity, reduced fasting glucose and HbA1c, and increased VO₂max, often comparably to MICT despite lower time commitment. Higher-volume protocols yielded greater HbA1c reductions; greater volume also strengthened benefits for fasting glucose, insulin and HOMA-IR. Combined HIIT plus diet produced the best BMI outcomes, while clamp-derived insulin sensitivity improvements partly depended on ≥3 % weight loss. Superiority over MICT varied by outcome and protocol. Conclusions. HIIT delivers meaningful gains in insulin sensitivity and metabolic health that are frequently comparable to MICT with substantially less time. Larger standardised trials are needed to define optimal, individualised prescriptions for type 2 diabetes prevention.
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76161
Open AccessThe effects of high intensity interval training (HIIT) on insulin sensitivity and metabolic health in adults with prediabetes
Background. Prediabetes elevates lifetime risk of type 2 diabetes and cardiovascular disease. Moderate-intensity continuous training (MICT) improves metabolic health but is limited by time demands. High-intensity interval training (HIIT) is a time-efficient alternative that can match or exceed MICT benefits for insulin sensitivity and glycemic control, yet optimal protocols remain unclear. Aim. To evaluate the effects of HIIT on insulin sensitivity and metabolic health in adults with prediabetes. Material and methods. PubMed, Scopus and Google Scholar were searched for English-language peer-reviewed studies (2015–2026) on HIIT and insulin sensitivity or metabolic outcomes in adults with prediabetes. Eligible randomised controlled trials, controlled trials, observational studies and reviews were screened by title/abstract and full text after duplicate removal; reference lists were also hand-searched. Results. HIIT improved muscle and whole-body insulin sensitivity, reduced fasting glucose and HbA1c, and increased VO₂max, often comparably to MICT despite lower time commitment. Higher-volume protocols yielded greater HbA1c reductions; greater volume also strengthened benefits for fasting glucose, insulin and HOMA-IR. Combined HIIT plus diet produced the best BMI outcomes, while clamp-derived insulin sensitivity improvements partly depended on ≥3 % weight loss. Superiority over MICT varied by outcome and protocol. Conclusions. HIIT delivers meaningful gains in insulin sensitivity and metabolic health that are frequently comparable to MICT with substantially less time. Larger standardised trials are needed to define optimal, individualised prescriptions for type 2 diabetes prevention.
- Open Access
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76169
GLP-1 Receptor Agonists Beyond Metabolic Control: Cardiovascular Benefits, Renal Protection, Neurological Effects and Socioeconomic Implications of Widespread Use.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used in type 2 diabetes and obesity. Evidence suggests additional cardiovascular, renal, and neurological effects, with important socioeconomic implications. Aim: To evaluate GLP-1 RA effects beyond metabolic control, focusing on cardiovascular, renal, neurological, physical activity, and socioeconomic outcomes. Material and methods: PubMed, Embase, and Scopus were searched for studies published from 2022 to 2026. Adult human studies assessing cardiovascular, renal, cerebrovascular, neurological or socioeconomic outcomes were included. After screening, 39 publications were qualitatively synthesized. Results: GLP-1 RAs were associated with reduced major adverse cardiovascular events, cardiovascular mortality, myocardial infarction, and selected heart-failure outcomes. Semaglutide reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease. Neurological effects included reduced cerebrovascular events and intracranial pressure, while evidence regarding cognition and neurodegenerative disorders remained heterogeneous. Conclusions: GLP-1 RAs exert multisystem effects beyond metabolic control, including cardiovascular and renal protection and neurological effects. Their expanding use may provide substantial health benefits but also raises concerns regarding treatment costs and socioeconomic disparities in access.
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76169
Open AccessGLP-1 Receptor Agonists Beyond Metabolic Control: Cardiovascular Benefits, Renal Protection, Neurological Effects and Socioeconomic Implications of Widespread Use.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used in type 2 diabetes and obesity. Evidence suggests additional cardiovascular, renal, and neurological effects, with important socioeconomic implications. Aim: To evaluate GLP-1 RA effects beyond metabolic control, focusing on cardiovascular, renal, neurological, physical activity, and socioeconomic outcomes. Material and methods: PubMed, Embase, and Scopus were searched for studies published from 2022 to 2026. Adult human studies assessing cardiovascular, renal, cerebrovascular, neurological or socioeconomic outcomes were included. After screening, 39 publications were qualitatively synthesized. Results: GLP-1 RAs were associated with reduced major adverse cardiovascular events, cardiovascular mortality, myocardial infarction, and selected heart-failure outcomes. Semaglutide reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease. Neurological effects included reduced cerebrovascular events and intracranial pressure, while evidence regarding cognition and neurodegenerative disorders remained heterogeneous. Conclusions: GLP-1 RAs exert multisystem effects beyond metabolic control, including cardiovascular and renal protection and neurological effects. Their expanding use may provide substantial health benefits but also raises concerns regarding treatment costs and socioeconomic disparities in access.
- Open Access
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76187
Treatments burden in adults with end stage renal disease receiving haemodialysis impact on medication adherence and health related quality of life.
Background: Haemodialysis imposes substantial treatment burden, affecting medication adherence and health-related quality of life (HRQoL). This study assessed treatment burden and its associations with these outcomes in adults receiving haemodialysis. Aim: To assess treatment burden in adults with end-stage renal disease (ESRD) receiving haemodialysis and examine its associations with medication adherence and HRQoL. Materials and Methods: A systematic search of PubMed, Embase and Scopus was conducted for publications from 2000 to 2026. After deduplication of 290 records, manual screening yielded 37 eligible studies — restricted to systematic reviews, meta-analyses, clinical trials, and Mendelian randomisation analyses involving adults (≥18 years). Results: Treatment burden in haemodialysis patients is multidimensional, encompassing high pill burden, time demands and significant psychological distress. Non-adherence rates reached up to 50%, driven by regimen complexity, depression, and caregiver strain. Physical HRQoL was more severely impaired than mental HRQoL, with fatigue and musculoskeletal symptoms as primary drivers. Longer dialysis vintage correlated with progressive symptom worsening Conclusions: Treatment burden in ESRD patients undergoing haemodialysis significantly impairs medication adherence and HRQoL, particularly in physical domains. Integrated, patient-centred strategies, including regimen simplification and psychosocial support, are needed.
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76187
Open AccessTreatments burden in adults with end stage renal disease receiving haemodialysis impact on medication adherence and health related quality of life.
Background: Haemodialysis imposes substantial treatment burden, affecting medication adherence and health-related quality of life (HRQoL). This study assessed treatment burden and its associations with these outcomes in adults receiving haemodialysis. Aim: To assess treatment burden in adults with end-stage renal disease (ESRD) receiving haemodialysis and examine its associations with medication adherence and HRQoL. Materials and Methods: A systematic search of PubMed, Embase and Scopus was conducted for publications from 2000 to 2026. After deduplication of 290 records, manual screening yielded 37 eligible studies — restricted to systematic reviews, meta-analyses, clinical trials, and Mendelian randomisation analyses involving adults (≥18 years). Results: Treatment burden in haemodialysis patients is multidimensional, encompassing high pill burden, time demands and significant psychological distress. Non-adherence rates reached up to 50%, driven by regimen complexity, depression, and caregiver strain. Physical HRQoL was more severely impaired than mental HRQoL, with fatigue and musculoskeletal symptoms as primary drivers. Longer dialysis vintage correlated with progressive symptom worsening Conclusions: Treatment burden in ESRD patients undergoing haemodialysis significantly impairs medication adherence and HRQoL, particularly in physical domains. Integrated, patient-centred strategies, including regimen simplification and psychosocial support, are needed.
- Open Access
- 8 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73300
Impact of Telehealth on Chronic Disease Control: A Narrative Review
Background. With the continuous development of new technologies, especially digital technologies, the possibilities provided by telehealth continue to increase. Research shows that the use of telehealth tools can be successfully used for managing patients with chronic conditions. Aim. As the number of chronic conditions within the world’s population rises, their effect becomes evident in terms of lowering patients’ quality of life and life expectancy. Telehealth can be an effective solution to this growing problem. This review is intended to examine the state-of-the-art studies in relation to the effect of telehealth on chronic disorder management, focusing mainly on clinical outcomes, quality of life, and healthcare costs. Material and methods. We reviewed the available scientific literature in databases such as PubMed, Scopus, and Web of Science. We included original research studies, systematic reviews, and meta-analyses that examined the impact of telehealth technologies on the management of patients with chronic diseases and were published in Polish or English between January 2020 and May 2026. Results. From the cited literature, it is clear that the use of telehealth has shown effectiveness in managing chronic disease. Although positive results can be observed in the short-term control of diseases such as hypertension, heart failure, diabetes, asthma, and chronic obstructive pulmonary disease, the effects of long-term management are unknown. Conclusions. This narrative review provides important insights regarding both the possible benefits and constraints of telehealth when managing chronic diseases. With the increasing use of telemedicine, it is vital to consider such difficulties and make sure that telehealth is accessible and efficient for all chronic patients.
- 8 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73300
Open AccessImpact of Telehealth on Chronic Disease Control: A Narrative Review
Background. With the continuous development of new technologies, especially digital technologies, the possibilities provided by telehealth continue to increase. Research shows that the use of telehealth tools can be successfully used for managing patients with chronic conditions. Aim. As the number of chronic conditions within the world’s population rises, their effect becomes evident in terms of lowering patients’ quality of life and life expectancy. Telehealth can be an effective solution to this growing problem. This review is intended to examine the state-of-the-art studies in relation to the effect of telehealth on chronic disorder management, focusing mainly on clinical outcomes, quality of life, and healthcare costs. Material and methods. We reviewed the available scientific literature in databases such as PubMed, Scopus, and Web of Science. We included original research studies, systematic reviews, and meta-analyses that examined the impact of telehealth technologies on the management of patients with chronic diseases and were published in Polish or English between January 2020 and May 2026. Results. From the cited literature, it is clear that the use of telehealth has shown effectiveness in managing chronic disease. Although positive results can be observed in the short-term control of diseases such as hypertension, heart failure, diabetes, asthma, and chronic obstructive pulmonary disease, the effects of long-term management are unknown. Conclusions. This narrative review provides important insights regarding both the possible benefits and constraints of telehealth when managing chronic diseases. With the increasing use of telemedicine, it is vital to consider such difficulties and make sure that telehealth is accessible and efficient for all chronic patients.
- Open Access
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73141
Polypharmacy in Elderly Patients: Clinical Risks, Drug Interactions and Strategies for Optimization – A Narrative Review
Background. Population aging and the growing prevalence of multimorbidity have led to an increasing number of older adults receiving multiple medications. Polypharmacy, commonly defined as the use of five or more medications, is associated with adverse drug reactions, drug interactions, functional decline, hospitalization, and mortality. Age-related physiological changes further increase susceptibility to medication-related harm. Aim. To review the epidemiology, clinical risks, drug interactions, and optimization strategies associated with polypharmacy in elderly patients. Material and methods. A narrative review of the literature was conducted using peer-reviewed articles, clinical guidelines, and consensus documents addressing polypharmacy in adults aged 65 years and older. Evidence related to epidemiology, pharmacological changes associated with aging, adverse drug events, assessment tools, potentially inappropriate medications, and optimization strategies was analyzed and synthesized narratively. Results. Polypharmacy is highly prevalent among older adults, especially those with multimorbidity and frailty. Age-related pharmacokinetic and pharmacodynamic changes increase the risk of adverse drug reactions and clinically significant drug interactions. Common consequences include falls, delirium, cognitive impairment, hospitalization, and increased mortality. Tools such as the Beers Criteria, STOPP/START criteria, and Medication Appropriateness Index help identify inappropriate prescribing. Key optimization strategies include comprehensive geriatric assessment, medication review, deprescribing, and interdisciplinary care. Conclusions. Polypharmacy remains a major challenge in geriatric care. Regular medication review, individualized treatment planning, and deprescribing interventions are essential to reduce medication-related harm and improve clinical outcomes in older adults.
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73141
Open AccessPolypharmacy in Elderly Patients: Clinical Risks, Drug Interactions and Strategies for Optimization – A Narrative Review
Background. Population aging and the growing prevalence of multimorbidity have led to an increasing number of older adults receiving multiple medications. Polypharmacy, commonly defined as the use of five or more medications, is associated with adverse drug reactions, drug interactions, functional decline, hospitalization, and mortality. Age-related physiological changes further increase susceptibility to medication-related harm. Aim. To review the epidemiology, clinical risks, drug interactions, and optimization strategies associated with polypharmacy in elderly patients. Material and methods. A narrative review of the literature was conducted using peer-reviewed articles, clinical guidelines, and consensus documents addressing polypharmacy in adults aged 65 years and older. Evidence related to epidemiology, pharmacological changes associated with aging, adverse drug events, assessment tools, potentially inappropriate medications, and optimization strategies was analyzed and synthesized narratively. Results. Polypharmacy is highly prevalent among older adults, especially those with multimorbidity and frailty. Age-related pharmacokinetic and pharmacodynamic changes increase the risk of adverse drug reactions and clinically significant drug interactions. Common consequences include falls, delirium, cognitive impairment, hospitalization, and increased mortality. Tools such as the Beers Criteria, STOPP/START criteria, and Medication Appropriateness Index help identify inappropriate prescribing. Key optimization strategies include comprehensive geriatric assessment, medication review, deprescribing, and interdisciplinary care. Conclusions. Polypharmacy remains a major challenge in geriatric care. Regular medication review, individualized treatment planning, and deprescribing interventions are essential to reduce medication-related harm and improve clinical outcomes in older adults.
- Open Access
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61
The role of regular physical activity on the prevention and alleviation of gastroesophageal reflux disease and chronic constipation in patients with sedentary lifestyle
Background. Gastroesophageal reflux disease (GERD) and chronic constipation represent two of the most common functional gastrointestinal disorders, with elevated prevalence among sedentary individuals. Prolonged sitting acts as a risk factor by increasing intraabdominal pressure, compromising lower esophageal sphincter integrity, delaying colonic transit, impairing pelvic floor strength and inducing adverse shifts in gut microbiota. Aim. This study aimed to evaluate the impact of physical activity and sedentary behaviour on the development and management of GERD and chronic constipation Material and methods. This narrative review analyzed recent publications, predominantly from 2024–2026, identified through manual searches in PubMed, Embase, and Scopus using keywords related to physical activity, sedentary behaviour, GERD, and chronic constipation. Results. For chronic constipation, physical activity consistently accelerates intestinal transit, boosts colonic motility, promotes beneficial microbiota changes, and decreases risk by 30-34% at higher activity levels. Benefits are most pronounced with moderate aerobic modalities and are potentiated by concurrent dietary improvements. Conclusions. Moderate-intensity physical activity is an effective, safe, and low-cost strategy for preventing and managing GERD and chronic constipation. It improves reflux symptoms and bowel function, while high-intensity exercise may aggravate GERD. Reducing sedentary behavior is essential alongside increasing activity levels. Combined lifestyle interventions, including diet, provide the greatest benefit. A “movement-first” approach should be integrated into routine care. Further randomized controlled trials are required to establish optimal exercise prescriptions and clarify diet–activity interactions.
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61
Open AccessThe role of regular physical activity on the prevention and alleviation of gastroesophageal reflux disease and chronic constipation in patients with sedentary lifestyle
Background. Gastroesophageal reflux disease (GERD) and chronic constipation represent two of the most common functional gastrointestinal disorders, with elevated prevalence among sedentary individuals. Prolonged sitting acts as a risk factor by increasing intraabdominal pressure, compromising lower esophageal sphincter integrity, delaying colonic transit, impairing pelvic floor strength and inducing adverse shifts in gut microbiota. Aim. This study aimed to evaluate the impact of physical activity and sedentary behaviour on the development and management of GERD and chronic constipation Material and methods. This narrative review analyzed recent publications, predominantly from 2024–2026, identified through manual searches in PubMed, Embase, and Scopus using keywords related to physical activity, sedentary behaviour, GERD, and chronic constipation. Results. For chronic constipation, physical activity consistently accelerates intestinal transit, boosts colonic motility, promotes beneficial microbiota changes, and decreases risk by 30-34% at higher activity levels. Benefits are most pronounced with moderate aerobic modalities and are potentiated by concurrent dietary improvements. Conclusions. Moderate-intensity physical activity is an effective, safe, and low-cost strategy for preventing and managing GERD and chronic constipation. It improves reflux symptoms and bowel function, while high-intensity exercise may aggravate GERD. Reducing sedentary behavior is essential alongside increasing activity levels. Combined lifestyle interventions, including diet, provide the greatest benefit. A “movement-first” approach should be integrated into routine care. Further randomized controlled trials are required to establish optimal exercise prescriptions and clarify diet–activity interactions.
- Open Access
- 17 April 2026
- Published by John Paul II University in Biała Podlaska in Health Problems of Civilization
Sudden cardiac arrest and sudden cardiac death in athletes: an updated perspective
Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in athletes are rare but catastrophic events that generate substantial medical, ethical, and public health concern. Although regular physical activity is associated with significant cardiovascular benefits, intense training and competition may unmask underlying structural or electrical heart diseases in susceptible individuals. The most common causes of SCA and SCD in young athletes include hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, left ventricular hypertrophy, myocarditis, congenital coronary artery anomalies, and primary electrical disorders such as long QT syndrome. In athletes over 35 years of age, asymptomatic atherosclerotic cardiovascular disease predominates. Pre-participation cardiovascular screening, including medical history, physical examination, and, in some regions, electrocardiography (ECG) aims to identify individuals at risk. However, controversy persists regarding the sensitivity, specificity, cost-effectiveness, and potential for false-positive findings associated with screening strategies. Rapid recognition of SCA, immediate cardiopulmonary resuscitation, and early defibrillation with automated external defibrillators (AEDs) remain critical determinants of survival. The aim of this review is to summarize current evidence on the epidemiology, risk stratification, screening strategies, and emergency management of SCA and SCD in athletes and to highlight ongoing challenges and areas for future research.
- 17 April 2026
- Published by John Paul II University in Biała Podlaska in Health Problems of Civilization
Open AccessSudden cardiac arrest and sudden cardiac death in athletes: an updated perspective
Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in athletes are rare but catastrophic events that generate substantial medical, ethical, and public health concern. Although regular physical activity is associated with significant cardiovascular benefits, intense training and competition may unmask underlying structural or electrical heart diseases in susceptible individuals. The most common causes of SCA and SCD in young athletes include hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, left ventricular hypertrophy, myocarditis, congenital coronary artery anomalies, and primary electrical disorders such as long QT syndrome. In athletes over 35 years of age, asymptomatic atherosclerotic cardiovascular disease predominates. Pre-participation cardiovascular screening, including medical history, physical examination, and, in some regions, electrocardiography (ECG) aims to identify individuals at risk. However, controversy persists regarding the sensitivity, specificity, cost-effectiveness, and potential for false-positive findings associated with screening strategies. Rapid recognition of SCA, immediate cardiopulmonary resuscitation, and early defibrillation with automated external defibrillators (AEDs) remain critical determinants of survival. The aim of this review is to summarize current evidence on the epidemiology, risk stratification, screening strategies, and emergency management of SCA and SCD in athletes and to highlight ongoing challenges and areas for future research.